17-1338-42
antibody from Invitrogen Antibodies
Targeting: PROM1
AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4
Antibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [10]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-1338-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD133 (Prominin-1) Monoclonal Antibody (TMP4), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The TMP4 monoclonal antibody reacts with human CD133 (Prominin-1), a 120 kDa member of the pentaspan family of proteins, which also includes Prominin-2. Their expression is found within plasma membrane protrusions such as epithelial microvilli. CD133 can exist in a number of alternatively spliced isoforms, and the protein has several N-linked glycosylation sites: the occurrence of both may be tissue-dependent. Human CD133 was first identified as an epitope expressed on CD34+ hematopoietic progenitors. Although the ligand and function of CD133 remain unknown, it has since proven to be very useful as a marker for both stem cells and cancer stem cells. In addition to its expression on hematopoietic precursors, CD133 has been used to identify tumorigenic colon cancer stem cells, brain cancer stem cells, prostate cancer stem cells, in addition to others. The binding of the TMP4 antibody does not block the binding of another anti-human CD133 antibody, EMK08 (Product # 12-1339) indicating that they recognize distinct epitopes. Applications Reported: This TMP4 antibody has been reported for use in flow cytometric analysis. Applications Tested: This TMP4 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- TMP4
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Curcumin Enhances Radiosensitization of Nasopharyngeal Carcinoma via Mediating Regulation of Tumor Stem-like Cells by a CircRNA Network.
High expression of endothelial progenitor cell-induced angiogenic markers is associated with bile acid levels in HCC.
Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis.
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness.
FZD5 contributes to TNBC proliferation, DNA damage repair and stemness.
Profiling and Targeting of Energy and Redox Metabolism in Grade 2 Bladder Cancer Cells with Different Invasiveness Properties.
Loss of Disabled-2 Expression in Pancreatic Cancer Progression.
Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.
Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin.
ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways.
Immunophenotypic comparison of heterogenous non-sorted versus sorted mononuclear cells from human umbilical cord blood: a novel cell enrichment approach.
Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells.
Comparative evaluation of differentiation potential of menstrual blood- versus bone marrow-derived stem cells into hepatocyte-like cells.
Detection and validation of circulating endothelial cells, a blood-based diagnostic marker of acute myocardial infarction.
Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells.
Human cardiac stem cells isolated from atrial appendages stably express c-kit.
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
Identification of human brain tumour initiating cells.
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Zhu D, Shao M, Yang J, Fang M, Liu S, Lou D, Gao R, Liu Y, Li A, Lv Y, Mo Z, Fan Q
Journal of Cancer 2020;11(8):2360-2370
Journal of Cancer 2020;11(8):2360-2370
High expression of endothelial progenitor cell-induced angiogenic markers is associated with bile acid levels in HCC.
Chen JL, Wang L, Li R, Jiao YF, Yu WF
Oncology letters 2020 Sep;20(3):2729-2738
Oncology letters 2020 Sep;20(3):2729-2738
Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis.
Jia J, Yu F, Xiong Y, Wei W, Ma H, Nisi F, Song X, Yang L, Wang D, Yuan G, Zhou H
Lipids in health and disease 2020 Sep 20;19(1):207
Lipids in health and disease 2020 Sep 20;19(1):207
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N, Padi SKR, Bearss JJ, Pandey R, Okumura K, Beltran H, Song JH, Kraft AS, Olive V
Molecular oncology 2020 May;14(5):974-990
Molecular oncology 2020 May;14(5):974-990
The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness.
Li F, Hu Q, He T, Xu J, Yi Y, Xie S, Ding L, Fu M, Guo R, Xiao ZJ, Niu M
Cancers 2020 Jun 15;12(6)
Cancers 2020 Jun 15;12(6)
FZD5 contributes to TNBC proliferation, DNA damage repair and stemness.
Sun Y, Wang Z, Na L, Dong D, Wang W, Zhao C
Cell death & disease 2020 Dec 12;11(12):1060
Cell death & disease 2020 Dec 12;11(12):1060
Profiling and Targeting of Energy and Redox Metabolism in Grade 2 Bladder Cancer Cells with Different Invasiveness Properties.
Pasquale V, Ducci G, Campioni G, Ventrici A, Assalini C, Busti S, Vanoni M, Vago R, Sacco E
Cells 2020 Dec 11;9(12)
Cells 2020 Dec 11;9(12)
Loss of Disabled-2 Expression in Pancreatic Cancer Progression.
Hocevar BA
Scientific reports 2019 May 17;9(1):7532
Scientific reports 2019 May 17;9(1):7532
Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.
Hung JJ, Kao YS, Huang CH, Hsu WH
Scientific reports 2019 Feb 28;9(1):2991
Scientific reports 2019 Feb 28;9(1):2991
Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin.
Huang W, Bei L, Eklund EA
Oncotarget 2018 May 25;9(40):25891-25902
Oncotarget 2018 May 25;9(40):25891-25902
ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways.
Wang F, Wang AY, Chesnelong C, Yang Y, Nabbi A, Thalappilly S, Alekseev V, Riabowol K
Oncogene 2018 Jan 18;37(3):286-301
Oncogene 2018 Jan 18;37(3):286-301
Immunophenotypic comparison of heterogenous non-sorted versus sorted mononuclear cells from human umbilical cord blood: a novel cell enrichment approach.
Indumathi S, Harikrishnan R, Rajkumar JS, Dhanasekaran M
Cytotechnology 2015 Jan;67(1):107-14
Cytotechnology 2015 Jan;67(1):107-14
Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells.
Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M
PloS one 2014;9(4):e94621
PloS one 2014;9(4):e94621
Comparative evaluation of differentiation potential of menstrual blood- versus bone marrow-derived stem cells into hepatocyte-like cells.
Khanjani S, Khanmohammadi M, Zarnani AH, Akhondi MM, Ahani A, Ghaempanah Z, Naderi MM, Eghtesad S, Kazemnejad S
PloS one 2014;9(2):e86075
PloS one 2014;9(2):e86075
Detection and validation of circulating endothelial cells, a blood-based diagnostic marker of acute myocardial infarction.
Li C, Wu Q, Liu B, Yao Y, Chen Y, Zhang H, Wang C, Cao J, Ge S
PloS one 2013;8(3):e58478
PloS one 2013;8(3):e58478
Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells.
Zou J, Zou P, Wang J, Li L, Wang Y, Zhou D, Liu L
Annals of hematology 2012 Jun;91(6):813-23
Annals of hematology 2012 Jun;91(6):813-23
Human cardiac stem cells isolated from atrial appendages stably express c-kit.
He JQ, Vu DM, Hunt G, Chugh A, Bhatnagar A, Bolli R
PloS one 2011;6(11):e27719
PloS one 2011;6(11):e27719
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
O'Brien CA, Pollett A, Gallinger S, Dick JE
Nature 2007 Jan 4;445(7123):106-10
Nature 2007 Jan 4;445(7123):106-10
Identification of human brain tumour initiating cells.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB
Nature 2004 Nov 18;432(7015):396-401
Nature 2004 Nov 18;432(7015):396-401
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW
Blood 1997 Dec 15;90(12):5002-12
Blood 1997 Dec 15;90(12):5002-12
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD45 PE (Product # 12-9459-42) and Mouse IgG1 K Isotype Control APC (Product # 17-4714-81) (left) or Anti-Human CD133 APC (right). Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 AKT expression in CD133/CD44 sorted cells. A) DLD-1 cells were sorted by flow cytometry and different populations with CD44 positive /CD133 negative (Q1), CD44 positive /CD133 positive (Q2), CD44 negative CD133 negative (Q3), were collected. B) The sorted cells were further analyzed with western blot for total AKT, AKT1 or AKT2 and betaactin expression.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Flow cytometry analysis of the expression of CD133, CD24 and CD44 in the colon cancer cell-line DLD-1 with its isogenic knock-out cell-lines of AKT 1, AKT 2 and AKT 1/2. A) In the parental cells, approximately 10% of the cells were CD133 positive cells. However, in the AKT 1 and AKT 1/2 knock-outs, the CD133 positive cells were reduced to 0.3 and 0.1% respectively. This was not seen in the AKT 2 knock-out cell-line, where 33% of the cells were positive for CD133. B) The mean fluorescent intensity of CD44 normalized to the DLD-1 parental cell-line increased to 150% in AKT 1 KO, 160% in AKT 2 KO and 300% in AKT 1/2 KO cell-line. The error bars represent the standard deviation (SD) from at least two experiments. C) The percent of CD24 positive cells analyzed with two different CD24 antibodies from BD Biosciences and Miltenyi/MACS in flow cytometry. The standard deviations are from repeated experiments. D) Cell-cycle distribution in DLD-1 parental, AKT 1 KO, AKT 2 KO and AKT 1/2 KO cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 Identification of EPCs. a Adherent cells grew in a blood island manner. Fluorescent staining of EPCs. b Adherent cells took up UEA-1-lectin. c Adherent cells took up Dil-Ac-LDL. d Adherent cells took up UEA-1-lectin and Dil-Ac-LDL. E. Surface molecular markers of EPCs. Adherent cells expressed CD34, CD133, CD14 and VEGFR-2. All experiments involving cell culture studies were repeated three times with three replicates per experiment
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Stemness markers of monolayers and spheroids from RT112 and 5637 cells. ( a - c ) Median fluorescence intensity of Aldefluor TM ( a ), CD44 ( b ) and CD133 ( c ) by flow cytometry analysis on RT112 and 5637 cells grown as monolayers. Results are the mean of two ( a ) and three ( b , c ) experimental replicates. Statistical test: t -test, * for p < 0.05. ( d ) Representative images from confocal immunofluorescence (IF) microscopy of RT112 and 5637 cells using SOX2 Antibody (red) and Hoechst 33342 (blue) for nuclei. Cells were grown as monolayer or spheroids on different (Tissue culture-treated, Not-treated or Cell repellent) supports, before being seeded in adherent condition on chamber slides for IF.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 USP4 promotes lung cancer cell stemness and its high expression is correlated with human lung cancer patients. ( A ) The Oncomine dataset ""Bhattacharjee Lung"" was used to analyze Pearson correlation of USP4 and Oct4/Sox2 expression. ( B - E ) H1975 cells stably expressing shRNA against USP4 (shUSP4-#1 or shUSP4-#2) were subjected to ( B ) Western blot analyses, ( C - D ) FACS analyses for CD133-stained cells or ( E ) tumorsphere formation assay. Respective images and quantitation were shown. Data from three independent experiments in triplicates were presented as means +- SD. *** p < 0.001. Scale bar = 100 mum. ( F - I ) H1975 cells stably expressing Flag-USP4 or Flag-USP4 C311A were subjected to ( F ) Western blot analyses, ( G ) FACS analyses for CD133-stained cells or ( H - I ) tumorsphere formation assay. Respective images and quantitation were shown. Data from three independent experiments in duplicates were presented as means +- SD. ** p < 0.01, *** p < 0.001. Scale bar = 100 mum. ( J ) The Oncomine dataset ""Gaber lung"" was used to analyze USP4 mRNA levels in normal human lung tissues and lung cancers. ( K ) The Oncomine dataset ""Bild lung"" was used to analyze USP4 mRNA levels in stage I or stage II-IV human lung cancers. ( L ) The Oncomine dataset ""Raponi lung"" was used to analyze USP4 mRNA levels in 3 year-alive or 3 year-dead human lung cancer patients.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Fap1-inhibition decreases abundance of CD133 + CD44 + cells in in a murine xenograft model of colon cancer with or without oxaliplatin Tumors from the mice described above were analyzed for cell population distribution after various treatments. (A) Histograms from flow cytometry demonstrate decreased abundance of CD133 + CD44 + cells after treatment with SLV peptide with or without oxaliplatin. A representative histograms for each cohort is shown. (B) Treatment with SLV peptide decreases relative abundance of CD133 + CD44 + cells in xenograft tumors. Tumors were simultaneously harvested from mice treated with SLV peptide versus VLS control (when control group tumors were >2,000 mm 3 ) and analyzed for CD133 and CD44 expression by flow cytometry. Significant differences indicated by * , ** , or *** . (p2,000 mm 3 ) and analyzed for CD133 and CD44 expression by flow cytometry. Significant differences indicated by * , ** , or *** . (p